Industries > Pharma > Asthma and COPD Therapies: World Market 2013-2023

Asthma and COPD Therapies: World Market 2013-2023

PUBLISHED: 06 September 2013
PAGES: 360

WOOCS 2.2.1
SKU: N/A Categories: , ,

New study reveals sales potential of this large, expanding market

See what the future holds for asthma and COPD therapies. Visiongain's report gives you drug revenue predictions to 2023. You find data, trends, opportunities and commercial prospects.

That new study lets you assess forecasted sales at overall world market, submarket, product, company and national level. You see why the asthma and COPD market will grow, as we predict.

In our investigation you find revenue forecasting, growth rates and market shares. Also, you see qualitative analyses, R&D and commercial developments. You receive 114 tables, 210 charts and four research interviews, including two with executives from GSK.

The following sections highlight what you discover in the report.

Prospects for submarkets and products

In addition to analyses of the overall world market, you see revenue forecasting of three world-level submarkets to 2023:
• Bronchodilators (Mono-therapy)
• Anti-inflammatory drugs
• Combination drugs

Also, you see how 19 leading drugs – including Seretide/Advair, Singulair, Spiriva, Symbicort and Pulmicort – can perform to 2023.

Prospects for leading countries shown to 2023

Developments worldwide will influence the market, especially fast-rising demand in emerging countries. There will be many opportunities for asthma and COPD therapies.

You discover revenue forecasts to 2023 for eleven national markets:
• US
• Japan
• Germany, France, UK, Italy and Spain (EU5 nations)
• India
• China
• Brazil
• Russia.

This decade, revenues from India and China will be among the fastest growing worldwide. In particular, product launches from 2013 onwards will benefit regional and national markets.

Research and development activities

What's happening in the R&D drug pipeline? You see developmental trends there:
• Monoclonal antibodies
• Ultra-Long Acting Beta-2 Agonists
• Muscarinic Antagonist Beta-2 Agonists
• Anti-leukotriene agents
• LAMA/LABA Combinations
• Developments in delivery systems
• Developments in telehealth

Discover how technological progress changes the sector. Our investigation explains, bringing together many issues.

Prominent issues affecting the asthma and COPD market

Our study lets you assess industry trends and outlooks worldwide from 2013. As the work shows, many issues affect the industry and market:
• An increasingly mature asthma market
• Patient adherence
• Patient management techniques
• Reimbursement, regulations, patent expiries and generic competition
• An increasingly segregated patient population

You see discussions of technological, commercial and economic matters, with emphasis on organisations competing in the industry.

Discussions of leading companies and prospects for market growth

What will happen next? The pharmaceutical industry will improve treatments for asthma and COPD and increase revenues there from 2013 to 2023. The R&D pipeline is strong. Our work shows you what technologies and organisations hold greatest potential. See profiles of seven leading companies, including these:
• Boehringer Ingelheim
• Merck
• AstraZeneca

In general, a company profile gives you the following information:
• Discussion of a company's activities and outlook
• Assessment of its developments – mergers and acquisitions (M&A), new products, and collaborations.
• Forecasting of asthma and COPD drug revenues to 2023

Overall world revenue for that market area will reach $34.51bn in 2013, our report forecasts. Ageing populations, educational initiatives, improved drug delivery and new formulations will increase sales of asthma and COPD therapies.

Nine ways Asthma and COPD Therapies: World Market 2013-2023 benefits you

In particular, then, our study gives you the following knowledge on asthma and COPD therapies:
• Forecasted revenues to 2023 for the overall world market and submarkets
• Potential revenues of 19 leading products to 2023
• Potential revenues of 6 promising drugs that are currently in development
• Market forecasting to 2023 for the US, Japan, leading EU countries (Germany, France, the UK, Italy and Spain), India, China, Brazil and Russia.
• Assessment of companies – discussions of activities and outlooks
• Review of R&D pipelines by treatment area – progress and trends
• Opinions on the sector, including our research interviews with leaders in industry
• Investigation of competition and opportunities influencing sales
• Discussion of what stimulates and restrains the industry and market.

That work gives independent analyses from our primary and secondary research. You receive information found only in our report.

With our study, you find business intelligence to help you understand the future of that industry and market.

Ordering now lets you discover prospects for asthma and COPD therapies

Visiongain's study is for everybody needing commercial analyses of asthma and COPD therapies. You find data, trends and predictions there. Please order that report now.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

To view free sample pages of this report please click here

Download sample pages

Complete the form below to download your free sample pages for Asthma and COPD Therapies: World Market 2013-2023

Download sample pages

Complete the form below to download your free sample pages for Asthma and COPD Therapies: World Market 2013-2023

Latest Pharma news

“Global Ophthalmic Drugs market set to grow to $32bn by 2024” says Visiongain report

Successful harnessing of the opportunities for growth in the ophthalmic pharmaceuticals market will depend upon the development of novel products with technologies that increase clinical effectiveness and development of products for previously-untreated ophthalmic conditions.

15 August 2019


“Global Medical Device Contract Manufacturing market set to grow to $130bn by 2024” says new Visiongain report

The available reduced costs of outsourced manufacturing combined with access to the innovation power of CMOs are major drivers behind the decision to outsource manufacturing processes.

06 August 2019


“3D Printing for Healthcare market is worth $872 million in 2019” says Visiongain report

The main appeal of 3D printed healthcare products to professionals is that each unit can be personalised to fit the recipient.

02 August 2019


“Global Rare Disease Drugs market set to grow to $257bn by 2024” says new Visiongain report

It is difficult to investigate rare diseases as the pool of patients is very small and often results in inadequate clinical knowledge.

01 August 2019